近期论文
查看导师最新文章
（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）
Chen W#, Kuang Y#, Qiu HB#, Cao Z, Tu Y, Sheng Q, Eilers G, He Q, Li HL, Zhu M, Wang Y, Zhang R, Wu Y1, Meng F, Fletcher JA, Ou WB. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors. Cancer Res. 2017 Sep 15;77(18):5107-5117. IF 9.122 Zhang LY#, Wu JL#, Qiu HB#, Dong SS, Zhu YH, Lee VH, Qin YR, Li Y, Chen J, Liu HB, Bi J, Ma S, Guan XY, Fu L. PSCA acts as a tumor suppressor by facilitating the nuclear translocation of RB1CC1 in esophageal squamous cell carcinoma. Carcinogenesis. 2016 Mar;37(3):320-332. IF 5.105 Zhou ZG#, Chen JB#, Qiu HB#, Wang RJ, Chen JC, Xu L, Chen MS, Zhang YJ. Parecoxib prevents complications in hepatocellular carcinoma patients receiving hepatic transarterial chemoembolization: a prospective score-matched cohort study. Oncotarget. 2016 May 10;7(19):27938-45. IF 5.168 Xuechao Liu#, Haibo Qiu#, Yuying Huang, Dazhi Xu, Wei Li, Yuanfang Li, Yingbo Chen, Zhiwei Zhou*, Xiaowei Sun*. Impact of preoperative anemia on outcomes in patients undergoing curative resection for gastric cancer: a single‐institution retrospective analysis of 2163 Chinese patients. Cancer Med. 2018 Feb; 7(2): 360–369. IF 3.362 Wei Zhuang#, Jing‐Dun Xie#, Shan Zhou, Zhi‐Wei Zhou, Yi Zhou, Xiao‐Wei Sun, Xiu‐Hong Yuan, Min Huang, Si Liu, Shuang Xin, Qi‐Biao Su, Hai‐Bo Qiu*, Xue‐Ding Wang*. Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients? Cancer Med. 2018 Feb; 7(2): 317–324. IF 3.362 Seeruttun SR, Yuan S, Qiu HB#, Huang Y, Li Y, Liang Y, Guan Y, Zhan Y, Li W, Chen Y, Sun X, Xu D, Zhou Z. A comprehensive analysis comparing the eighth AJCC gastric cancer pathological classification to the seventh, sixth, and fifth editions. Cancer Med. 2017 Dec;6(12):2804-2813. IF 3.362 Liu X, Xu P, Qiu HB#, Xu D, Li W, Zhan Y, Li Y, Chen Y, Zhou Z, Sun X. Preoperative Nutritional Deficiency Is a Useful Predictor of Postoperative Outcome in Patients Undergoing Curative Resection for Gastric Cancer. Transl Oncol. 2016 Dec;9(6):482-488. IF 3.025 Liu X, Xu P, Qiu HB#, Liu J, Chen S, Xu D, Li W, Zhan Y, Li Y, Chen Y, Zhou Z, Sun X. Clinical utility of HER2 assessed by immunohistochemistry in patients undergoing curative resection for gastric cancer. Onco Targets Ther. 2016 Feb 26;9:949-58. IF 2.612 Hai-Bo Qiu#, Zhong-Guo Zhou#, Xing-Yu Feng#, Xue-Chao Liu, Jing Guo, Ming-Zhe Ma, Ying-Bo Chen, Xiao-Wei Sun*, Zhi-Wei Zhou*. Advanced gastrointestinal stromal tumor patients benefit from palliative surgery after tyrosine kinase inhibitors therapy. Medicine (Baltimore). 2018 Jan;97(2):e9097. IF 1.803 Qiu HB#, Zhuang W#, Wu T, Xin S, Lin CZ, Ruan HL, Zhu X, Huang M, Li JL, Hou XY, Zhou ZW, Wang XD. Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1. Pharmacogenomics J. 2017 Aug 1. doi: 10.1038/tpj.2017.40. IF 3.815 Liu X, Qiu HB#, Zhang P, Feng X, Chen T, Li Y, Tao K, Li G, Sun X, Zhou Z; China Gastrointestinal Stromal Tumor Study Group (CN-GIST). Prognostic role of tumor necrosis in patients undergoing curative resection for gastric gastrointestinal stromal tumor: a multicenter analysis of 740 cases in China. Cancer Med. 2017 Dec;6(12):2796-2803. IF 3.362 Liu X#, Qiu HB#, Zhang P, Feng X, Chen T, Li Y, Tao K, Li G, Sun X, Zhou Z; China Gastrointestinal Stromal Tumor Study Group (CN-GIST). Ki-67 labeling index may be a promising indicator to identify "very high risk" gastrointestinal stromal tumor (GIST): a multicenter retrospective study of 1022 patients. Hum Pathol. 2017 Sep 26. pii: S0046-8177(17)30345-3. IF 3.014 Liu X#, Qiu HB#, Liu J, Chen S, Xu D, Li W, Zhan Y, Li Y, Chen Y, Zhou Z, Sun X. A Novel Prognostic Score, Based on Preoperative Nutritional Status, Predicts Outcomes of Patients after Curative Resection for Gastric Cancer. J Cancer. 2016 Oct 25;7(14):2148-2156. IF 2.916 Zhuang W#, Qiu HB#, Chen XM, Yuan XH, Yang LF, Sun XW, Zhou XJ, Huang M, Wang XD, Zhou ZW. Simultaneous quantification of imatinib and its main metabolite N-demethyl-imatinib in human plasma by liquid chromatography-tandem mass spectrometry and its application to therapeutic drug monitoring in patients with gastrointestinal stromal tumor. Biomed Chromatogr. 2017 Dec;31(12). IF 1.601 Liu X, Qiu HB#, Kong P, Zhou Z, Sun X. Gastric cancer, nutritional status, and outcome. Onco Targets Ther. 2017 Apr 12; 10: 2107 - 2114. IF1.653 Qiu HB#, Zhang LY#, Ren C. Targeting CDH17 suppresses tumor progression in gastric cancer by downregulating wnt/β-catenin signaling. PLoS One. 2013;8(3):e56959. IF 2.806 Qiu HB#, Chen G, Keshari RP et.al. The extramural metastasis might be categorized in lymph node staging. BMC Cancer. 2011 Sep 26;11(1):414
京公网安备 11010802027423号